Home Featured Page 281

Featured

Latest

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

‘One-of-a-Kind’ $10 Million Psychedelic Research Center Comes to NYU

Red Light Holland iMicrodose Pack Receives Authorization for the First Legal...

Yukoterre Announces Conditional Approval of Reverse Takeover Transaction With Silo Wellness

PharmaDrug Files For FDA Orphan Drug Designation For DMT In Kidney...

Nova Mentis Autism Clinical Study Approved by Institutional Review Board

The Effects of Antidepressant Discontinuation on MDMA-Assisted Psychotherapy

Should You Listen to Music During Psychedelic Treatments? How Sounds Impact...

Will the Biden Administration Embrace Federal Psychedelic Reform?

1...280281282...299 Page 281 of 299

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

‘One-of-a-Kind’ $10 Million Psychedelic Research Center Comes to NYU

Red Light Holland iMicrodose Pack Receives Authorization for the First Legal...

Yukoterre Announces Conditional Approval of Reverse Takeover Transaction With Silo Wellness

PharmaDrug Files For FDA Orphan Drug Designation For DMT In Kidney...

Nova Mentis Autism Clinical Study Approved by Institutional Review Board

The Effects of Antidepressant Discontinuation on MDMA-Assisted Psychotherapy

Should You Listen to Music During Psychedelic Treatments? How Sounds Impact...

Interview With Christi Myers

Interview With Ronan Levy

Will the Biden Administration Embrace Federal Psychedelic Reform?

EDITOR PICKS

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY